BIOCRYST PHARMACEUTICALS
BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO™ (berotralstat) is approved in the United States for the prevention of HAE attacks in adult and pediatric patients 12 years and older, and under regulatory review for approval in Japan and the European Union. BioCryst has several ongoing development prog... rams including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, galidesivir, a potential treatment for COVID-19, Marburg virus disease and Yellow Fever, and BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva. RAPIVAB® (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, is BioCryst’s first approved product and has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan, Korea and the European Union. Post-marketing commitments for RAPIVAB are ongoing.
BIOCRYST PHARMACEUTICALS
Industry:
Biotechnology Clinical Trials Therapeutics
Founded:
1986-01-01
Address:
Birmingham, Alabama, United States
Country:
United States
Website Url:
http://www.biocryst.com
Total Employee:
101+
Status:
Active
Contact:
9198591314
Email Addresses:
[email protected]
Total Funding:
1.31 B USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Analytics Google Tag Manager WordPress Content Delivery Network Font Awesome Global Site Tag Sitelinks Search Box IPv6
Similar Organizations
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Hookipa Pharma
Hookipa is a clinical stage biotech company developing best-in-class active immunization therapies for infectious diseases and oncology.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2012-10-18 | Presidio Pharmaceuticals | Presidio Pharmaceuticals acquired by BioCryst Pharmaceuticals | 101 M USD |
| 2010-10-14 | Bioanalytical Laboratory Services | Bioanalytical Laboratory Services acquired by BioCryst Pharmaceuticals | N/A |
Investors List
Royalty Pharma
Royalty Pharma investment in Post-IPO Equity - BioCryst Pharmaceuticals
Ontario Municipal Employees Retirement System
Ontario Municipal Employees Retirement System investment in Post-IPO Equity - BioCryst Pharmaceuticals
Royalty Pharma
Royalty Pharma investment in Post-IPO Debt - BioCryst Pharmaceuticals
Athyrium Capital Management LP
Athyrium Capital Management LP investment in Post-IPO Debt - BioCryst Pharmaceuticals
MidCap Financial
MidCap Financial investment in Post-IPO Debt - BioCryst Pharmaceuticals
Centers for Disease Control and Prevention
Centers for Disease Control and Prevention investment in Grant - BioCryst Pharmaceuticals
MidCap Financial
MidCap Financial investment in Post-IPO Debt - BioCryst Pharmaceuticals
National Institutes of Health
National Institutes of Health investment in Post-IPO Equity - BioCryst Pharmaceuticals
National Institute of Allergy and Infectious Diseases
National Institute of Allergy and Infectious Diseases investment in Grant - BioCryst Pharmaceuticals
Key Employee Changes
Official Site Inspections
http://www.biocryst.com Semrush global rank: 2.09 M Semrush visits lastest month: 9.96 K
- Host name: 141.193.213.11
- IP address: 141.193.213.11
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
